Skip to main navigation Skip to search Skip to main content

A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

  • K. H. Kim
  • , H. J. Lee
  • , S. J. Lee
  • , M. Kim
  • , M. S. Ahn
  • , M. Y. Choi
  • , N. R. Lee
  • , M. Jung
  • , S. J. Shin

Research output: Contribution to journalArticlepeer-review

1 Scopus citations
Original languageEnglish
Pages (from-to)S85-S86
JournalEuropean Journal of Cancer
Volume174
DOIs
StatePublished - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this